Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho

被引:31
作者
Bygrave, Helen [1 ]
Kranzer, Katharina [2 ]
Hilderbrand, Katherine [3 ,4 ]
Jouquet, Guillaume [1 ]
Goemaere, Eric [3 ]
Vlahakis, Nathalie [1 ]
Trivino, Laura [1 ]
Makakole, Lipontso [5 ]
Ford, Nathan [3 ,4 ]
机构
[1] Med Sans Frontieres, Morija, Lesotho
[2] London Sch Hyg & Trop Med, London WC1, England
[3] Med Sans Frontieres, Cape Town, South Africa
[4] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7700 Rondebosch, South Africa
[5] Scott Hosp, Morija, Lesotho
来源
PLOS ONE | 2011年 / 6卷 / 03期
关键词
DISOPROXIL FUMARATE; THERAPY; HIV; OUTCOMES; ZAMBIA; DF;
D O I
10.1371/journal.pone.0017609
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction: Current guidelines contraindicate TDF use when creatinine clearance (CrCl) falls below 50 ml/min. We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho. Methods: We calculated changes in CrCl from baseline for patients initiated on TDF at 6 and 12 months and the proportion of patients initiated on TDF who developed renal impairment. Screening algorithms were developed using risk factors determined by multivariate analysis. Results: Among 933 adults for whom baseline creatinine was available, 176 (18.9%) presented with a baseline CrCl < 50 ml/min. Renal function improved during follow-up. 19 patients who developed renal toxicity during follow up remained on TDF; renal function improved (CrCl >= 50 ml/min) in all but 3 of these patients. Among 15 patients with a baseline CrCl,50 ml/min were started in error, none developed severe renal impairment. Conclusion: In this setting TDF-associated renal toxicity is rare and mainly transient. Further studies to assess TDF safety at lower CrCl thresholds are warranted.
引用
收藏
页数:5
相关论文
共 19 条
[1]  
[Anonymous], 2010, Clinical Guidelines for the Management of HIVAIDS in Adults and Adolescents
[2]  
[Anonymous], 2009, Rapid advice for antiretroviral therapy for HIV infection in adults and adolescents
[3]  
[Anonymous], 5 IAS C HIV PATH TRE
[4]  
[Anonymous], 2010, Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach
[5]   A Comparison of the Predictive Performance of Different Methods of Kidney Function Estimation in a Well-Characterized HIV-Infected Population [J].
Barraclough, Katherine ;
Er, Lee ;
Ng, Francisco ;
Harris, Marianne ;
Montaner, Julio ;
Levin, Adeera .
NEPHRON CLINICAL PRACTICE, 2009, 111 (01) :C39-C48
[6]   Early Clinical and Programmatic Outcomes with Tenofovir-Based Antiretroviral Therapy in Zambia [J].
Chi, Benjamin H. ;
Mwango, Albert ;
Giganti, Mark ;
Mulenga, Lloyd B. ;
Tambatamba-Chapula, Bushimbwa ;
Reid, Stewart E. ;
Bolton-Moore, Carolyn ;
Chintu, Namwinga ;
Mulenga, Priscilla L. ;
Stringer, Elizabeth M. ;
Sheneberger, Robert ;
Mwaba, Peter ;
Stringer, Jeffrey S. A. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (01) :63-70
[7]   Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years [J].
Cohen, Rachel ;
Lynch, Sharonann ;
Bygrave, Helen ;
Eggers, Evi ;
Vlahakis, Natalie ;
Hilderbrand, Katherine ;
Knight, Louise ;
Pillay, Prinitha ;
Saranchuk, Peter ;
Goemaere, Eric ;
Makakole, Lipontso ;
Ford, Nathan .
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2009, 12
[8]   Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV-Infected Patients [J].
Cooper, Ryan D. ;
Wiebe, Natasha ;
Smith, Nathaniel ;
Keiser, Philip ;
Naicker, Saraladevi ;
Tonelli, Marcello .
CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) :496-505
[9]   Renal impairment in a rural African antiretroviral programme [J].
Franey, Cara ;
Knott, Deborah ;
Barnighausen, Till ;
Dedicoat, Martin ;
Adam, Ahmed ;
Lessells, Richard J. ;
Newell, Marie-Louise ;
Cooke, Graham S. .
BMC INFECTIOUS DISEASES, 2009, 9 :143
[10]   Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV [J].
Gallant, JE ;
DeJesus, E ;
Arribas, JR ;
Pozniak, AL ;
Gazzard, B ;
Campo, RE ;
Lu, B ;
McColl, D ;
Chuck, S ;
Enejosa, J ;
Toole, JJ ;
Cheng, AK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (03) :251-260